Pure Global
NCT06332300

An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC

An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Lateral Ventricular Chemotherapy in Patients With Non-squamous NSCLC With Soft Meningeal Metastases Who Have Failed EGFR-TKI Therapy
Jiangsu Province Nanjing Brain Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
Adebelimumab+Famitinib + FOLFIRI+Ariely
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangsu Province Nanjing Brain Hospital
Location
Nanjing, China
Timeline & enrollment
Phase
Phase 2
Start date
Feb 01, 2024
End date
Feb 01, 2026
Enrollment
28 participants
Primary outcome

ORR

Summary

This study was a single-arm design to explore the efficacy and safety of Adebelimumab in
 combination with famitinib and lateral ventricular chemotherapy in patients with floppy
 meningeal metastases from non-squamous NSCLC who have failed EGFR-TKI therapy, and included
 patients with pathologically confirmed non-squamous non-small cell lung cancer.

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06332300
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06332300 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangsu Province Nanjing Brain Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.